United Kingdom (UK) Companion Diagnostics Market (2025-2031) | Industry, Competitive Landscape, Analysis, Size & Revenue, Share, Trends, Companies, Value, Forecast, Growth, Segmentation, Outlook

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United Kingdom (UK) Country Macro Economic Indicators

3.2 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, 2021 & 2031F

3.3 United Kingdom (UK) Companion Diagnostics Market - Industry Life Cycle

3.4 United Kingdom (UK) Companion Diagnostics Market - Porter's Five Forces

3.5 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume Share, By Technology Type, 2021 & 2031F

3.6 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume Share, By Indication, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of chronic diseases in the UK, leading to higher demand for personalized medicine and companion diagnostics.

4.2.2 Growing investments in healthcare infrastructure and research development activities in the UK.

4.2.3 Rising awareness among healthcare professionals and patients about the benefits of companion diagnostics in treatment decision-making.

4.3 Market Restraints

4.3.1 Stringent regulatory requirements and approval processes for companion diagnostics in the UK.

4.3.2 Limited reimbursement policies for companion diagnostics, affecting adoption rates among patients and healthcare providers.

4.3.3 High cost associated with developing and commercializing companion diagnostics, impacting market accessibility.

6.1 United Kingdom (UK) Companion Diagnostics Market, By Technology Type

6.1.1 Overview and Analysis

6.1.2 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Technology Type, 2021- 2031F

6.1.3 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Immunohistochemistry, 2021- 2031F

6.1.4 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Polymerase Chain Reaction (PCR), 2021- 2031F

6.1.5 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Next Generation Sequencing (NGS), 2021- 2031F

6.1.6 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By In Situ Hybridization, 2021- 2031F

6.1.7 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Others, 2021- 2031F

6.2 United Kingdom (UK) Companion Diagnostics Market, By Indication

6.2.1 Overview and Analysis

6.2.2 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Oncology, 2021- 2031F

6.2.3 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Neurology, 2021- 2031F

6.2.4 United Kingdom (UK) Companion Diagnostics Market Revenues & Volume, By Others, 2021- 2031F

7.1 United Kingdom (UK) Companion Diagnostics Market Export to Major Countries

7.2 United Kingdom (UK) Companion Diagnostics Market Imports from Major Countries

8.1 Adoption rate of companion diagnostics in UK healthcare facilities.

8.2 Number of partnerships and collaborations between diagnostic companies and pharmaceutical firms in the UK.

8.3 Rate of integration of companion diagnostics in clinical practice guidelines in the UK.

8.4 Level of government funding allocated to support companion diagnostics development and implementation in the UK.

8.5 Patient outcomes and treatment efficacy improvements attributed to the use of companion diagnostics in the UK.

9.1 United Kingdom (UK) Companion Diagnostics Market Opportunity Assessment, By Technology Type, 2021 & 2031F

9.2 United Kingdom (UK) Companion Diagnostics Market Opportunity Assessment, By Indication, 2021 & 2031F

10.1 United Kingdom (UK) Companion Diagnostics Market Revenue Share, By Companies, 2024

10.2 United Kingdom (UK) Companion Diagnostics Market Competitive Benchmarking, By Operating and Technical Parameters